Kringle Pharma’s project entitled ‘Recombinant human HGF for the treatment of acute spinal cord injury’ was accepted by Japan Agency for Medical Research and Development, AMED, as its Drug Discovery Support Promotion Project.

Kringle Pharma’s project entitled ‘Recombinant human HGF for the treatment of acute spinal cord injury’ was accepted by Japan Agency for Medical Research and Development, AMED, as its Drug Discovery Support Promotion Project.